Carl L. G. Hansen - 07 Dec 2021 Form 4 Insider Report for AbCellera Biologics Inc. (ABCL)

Role: Chief Executive Officer, Director, 10%+ Owner
Signature: /s/ Tryn Stimart, attorney in fact
Issuer symbol: ABCL
Transactions as of: 07 Dec 2021
Net transactions value: $0
Form type: 4
Filing time: 09 Dec 2021, 17:00:45 UTC
Previous filing: 22 Nov 2021
Next filing: 03 Feb 2022
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
holding	ABCL	Common Shares						224,500	07 Dec 2021	Direct
holding	ABCL	Common Shares						55,807,290	07 Dec 2021	See Footnote	F1
holding	ABCL	Common Shares						233,500	07 Dec 2021	See Footnote	F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	ABCL	Share Option (right to buy)	Award	$0	+920,312	+18%	$0.000000	5,913,122	07 Dec 2021	Common Shares	920,312	$14.55	Direct	F3

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	These shares are held by Thermopylae Holdings Ltd., which is an entity wholly owned by the Reporting Person.
F2	These shares are held by Hankla Family Trust (2019), of which the Reporting Person and his spouse are joint trustees. The Reporting Person disclaims beneficial ownership of such securities, except to the extent of his indirect pecuniary interest therein.
F3	The shares subject to such option vest and become exercisable quarterly in substantially equal installments over a four-year period, with the first tranche vested on December 7, 2022, subject to the Reporting Person's continuous service to the Issuer on each such date